Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Applicability of ischemic heart disease clinical practice guidelines in low- and middle-income countries.

International journal of cardiology·2026
Same author

iCARDIO Alliance global implementation guidelines for the management of obesity 2025 focus on prevention and treatment of cardiometabolic disease.

American journal of preventive cardiology·2026
Same author

IPTW-based synthetic patients and lab-grown artificial chicken: Scientific feats that must be served with clear labeling.

International journal of cardiology·2026
Same author

iCARDIO Alliance Global Implementation Guidelines on Heart Failure 2025.

Heart views : the official journal of the Gulf Heart Association·2026
Same author

Heart failure with reduced ejection fraction in Sweden: patient adherence and persistence to quadruple pharmacotherapy prescription.

European heart journal·2026
Same author

Cooperative Binding Domains Enhance Sensitivity and Overcome the Hook Effect in Two-Component Protein Biosensors.

ACS sensors·2026
Same journal

Interventions to prevent or cease electronic cigarette use in children and adolescents.

The Cochrane database of systematic reviews·2026
Same journal

Drugs to improve anaemia, quality of life, and physical function in people with myelodysplastic syndromes (MDS).

The Cochrane database of systematic reviews·2026
Same journal

Interventions for smoking cessation in inpatient psychiatry settings.

The Cochrane database of systematic reviews·2026
Same journal

Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

The Cochrane database of systematic reviews·2026
Same journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026
Same journal

Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

The Cochrane database of systematic reviews·2026
See all related articles

Related Experiment Video

Updated: May 24, 2026

Bedside Ultrasound for Guiding Fluid Removal in Patients with Pulmonary Edema: The Reverse-FALLS Protocol
07:59

Bedside Ultrasound for Guiding Fluid Removal in Patients with Pulmonary Edema: The Reverse-FALLS Protocol

Published on: July 28, 2018

Diuretics for heart failure.

Rajaa F Faris1, Marcus Flather, Henry Purcell

  • 1Department of Cardiology, Prince Sultan Cardiac Centre, P.O. Box: 7897, Riyadh, Saudi Arabia, 11565.

The Cochrane Database of Systematic Reviews
|February 17, 2012
PubMed
Summary
This summary is machine-generated.

Diuretics significantly reduce mortality and hospitalizations for worsening chronic heart failure compared to placebo. These treatments also enhance exercise capacity when compared to other active therapies in heart failure patients.

Related Experiment Videos

Last Updated: May 24, 2026

Bedside Ultrasound for Guiding Fluid Removal in Patients with Pulmonary Edema: The Reverse-FALLS Protocol
07:59

Bedside Ultrasound for Guiding Fluid Removal in Patients with Pulmonary Edema: The Reverse-FALLS Protocol

Published on: July 28, 2018

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Background:

  • Chronic heart failure (CHF) is a leading global cause of illness and death.
  • Diuretics are a primary treatment for CHF, offering symptomatic relief.
  • The impact of diuretics on CHF progression and patient survival remains uncertain.

Purpose of the Study:

  • To evaluate the benefits and harms of diuretic use in patients with chronic heart failure.
  • To synthesize evidence from randomized controlled trials on diuretic therapy for CHF.

Main Methods:

  • Systematic review of updated searches in major biomedical databases (Cochrane, MEDLINE, EMBASE) and manual searches.
  • Inclusion of double-blinded randomized controlled trials comparing diuretics with placebo or other active agents (e.g., ACE inhibitors, digoxin).
  • Independent data extraction and quality assessment by two authors; meta-analysis using fixed-effects models where appropriate.

Main Results:

  • The review included 14 trials with 525 participants.
  • Diuretic therapy was associated with significantly lower mortality (OR 0.24, P=0.02) and reduced hospital admissions for worsening heart failure (OR 0.07, P=0.01) compared to placebo.
  • Compared to active controls, diuretics improved exercise capacity (WMD 0.72, P<0.0001).

Conclusions:

  • Evidence from small trials suggests diuretics reduce mortality and hospitalizations for worsening heart failure in CHF patients.
  • Diuretics appear to improve exercise capacity when compared with active treatments.
  • Further research may be needed to fully elucidate the long-term effects of diuretics in CHF management.